高级检索
当前位置: 首页 > 详情页

Assessment of serum interleukin-28 as a biomarker to predict mortality in traumatic patients with sepsis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Trauma Ctr,Dept Emergency & Traumat Surg, Wuhan, Peoples R China [2]Huazhong Univ & Technol, Tongji Hosp, Tongji Med Coll, Trauma Ctr,Dept Emergency & Traumat Surg, 1095 Jiefang Rd, Wuhan 430030, Peoples R China
出处:
ISSN:

关键词: Sepsis Trauma Mortality IL-28A IL-28B

摘要:
Background: Serious trauma due to various factors is a major global public issue, and sepsis is a major cause of trauma-associated mortality. Timely diagnosis and suitable treatment of post-traumatic sepsis are crucial to improve the hospital outcome of traumatic patients. IL-28 is a newly discovered member of IFN-lambda family with multiple functions in inflammatory response. To date, its role in the pathogenic mechanisms of post-traumatic sepsis still remains unknown.Methods: In total, 20 healthy controls, 55 traumatic patients without sepsis and 54 traumatic patients with sepsis were enrolled in this study. Serum IL-28A/B levels were investigated by ELISA.Results: IL-28A/B levels were significantly increased in traumatic patients compared to healthy volunteers. Moreover, septic trauma patients displayed a significant increase in IL-28A/B levels compared with non-septic patients. In septic patients, IL-28A/B were negatively correlated with IFN-gamma, IL-5, IL-13 and IL-17, and posi-tively associated with IL-10. Moreover, IL-28A (AUC: 0.821, 95 %CI: 0.693-0.949) and IL-28B (AUC: 0.811, 95 % CI: 0.691-0.931) were both beneficial to predict increased mortality risk in septic trauma patients, though there was no statistical difference in the predictive value between them.Conclusions: Early serum levels of IL-28A/B were associated with the development of post-trauma sepsis and could be applied to assess the outcome of traumatic patients with sepsis. Thus, IL-28 may be a potential indicator for post-traumatic sepsis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 生化与分子生物学 3 区 细胞生物学 3 区 免疫学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 生化与分子生物学 3 区 细胞生物学 3 区 免疫学
JCR分区:
出版当年[2020]版:
Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 IMMUNOLOGY Q3 CELL BIOLOGY
最新[2023]版:
Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CELL BIOLOGY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Trauma Ctr,Dept Emergency & Traumat Surg, Wuhan, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Trauma Ctr,Dept Emergency & Traumat Surg, Wuhan, Peoples R China [2]Huazhong Univ & Technol, Tongji Hosp, Tongji Med Coll, Trauma Ctr,Dept Emergency & Traumat Surg, 1095 Jiefang Rd, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:434 今日访问量:0 总访问量:420 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)